The Fort Worth Press - Ketamine pill treats depression without psychedelic effects: study

USD -
AED 3.6725
AFN 63.511502
ALL 83.099858
AMD 378.311305
ANG 1.790083
AOA 916.999822
ARS 1376.702298
AUD 1.445713
AWG 1.80225
AZN 1.70203
BAM 1.69121
BBD 2.021203
BDT 123.152752
BGN 1.709309
BHD 0.377555
BIF 2980.6865
BMD 1
BND 1.282811
BOB 6.934122
BRL 5.247303
BSD 1.003511
BTN 94.391913
BWP 13.675591
BYN 2.974214
BYR 19600
BZD 2.018349
CAD 1.383711
CDF 2280.000129
CHF 0.79316
CLF 0.023276
CLP 919.100796
CNY 6.901503
CNH 6.918175
COP 3701.35
CRC 466.602389
CUC 1
CUP 26.5
CVE 95.347419
CZK 21.229715
DJF 178.70438
DKK 6.481105
DOP 60.504391
DZD 132.984075
EGP 52.825005
ERN 15
ETB 156.694439
EUR 0.86738
FJD 2.24825
FKP 0.747836
GBP 0.750185
GEL 2.69498
GGP 0.747836
GHS 10.97146
GIP 0.747836
GMD 73.495467
GNF 8795.921985
GTQ 7.680368
GYD 209.951965
HKD 7.823705
HNL 26.573681
HRK 6.536202
HTG 131.592942
HUF 336.973016
IDR 16917
ILS 3.127675
IMP 0.747836
INR 94.18755
IQD 1314.718815
IRR 1313150.00002
ISK 123.739852
JEP 0.747836
JMD 158.070639
JOD 0.708994
JPY 159.629018
KES 129.847903
KGS 87.44948
KHR 4024.402371
KMF 427.000109
KPW 900.057798
KRW 1506.120113
KWD 0.30748
KYD 0.83627
KZT 484.190774
LAK 21636.228425
LBP 89732.015462
LKR 315.615164
LRD 184.148973
LSL 16.90412
LTL 2.95274
LVL 0.60489
LYD 6.398976
MAD 9.352461
MDL 17.546954
MGA 4182.664038
MKD 53.45991
MMK 2099.983779
MNT 3583.827699
MOP 8.081059
MRU 39.984608
MUR 46.630031
MVR 15.449942
MWK 1740.168102
MXN 17.83826
MYR 3.994038
MZN 63.903947
NAD 16.904046
NGN 1385.640306
NIO 36.93215
NOK 9.636865
NPR 151.028367
NZD 1.730475
OMR 0.384485
PAB 1.003502
PEN 3.470204
PGK 4.335701
PHP 60.17404
PKR 280.088894
PLN 3.70628
PYG 6529.521635
QAR 3.659719
RON 4.421017
RSD 101.866996
RUB 82.394266
RWF 1465.35287
SAR 3.751605
SBD 8.042037
SCR 13.925209
SDG 600.999932
SEK 9.396885
SGD 1.284565
SHP 0.750259
SLE 24.549912
SLL 20969.510825
SOS 573.481661
SRD 37.340504
STD 20697.981008
STN 21.185616
SVC 8.781222
SYP 111.44287
SZL 16.913113
THB 32.879496
TJS 9.608761
TMT 3.5
TND 2.944775
TOP 2.40776
TRY 44.364103
TTD 6.823498
TWD 31.991302
TZS 2570.059002
UAH 44.060825
UGX 3713.071412
UYU 40.624149
UZS 12239.233167
VES 462.09036
VND 26351
VUV 119.023334
WST 2.74953
XAF 567.218502
XAG 0.014774
XAU 0.000225
XCD 2.702549
XCG 1.808646
XDR 0.705441
XOF 567.223406
XPF 103.126392
YER 238.650338
ZAR 17.076235
ZMK 9001.196955
ZMW 18.791291
ZWL 321.999592
  • BCC

    0.2300

    74.88

    +0.31%

  • RIO

    -1.5900

    85.95

    -1.85%

  • GSK

    -0.3200

    54.38

    -0.59%

  • NGG

    -1.8600

    82.43

    -2.26%

  • BTI

    -0.1400

    58.31

    -0.24%

  • AZN

    -3.4000

    183.74

    -1.85%

  • JRI

    0.0200

    12.12

    +0.17%

  • BCE

    0.0000

    25.49

    0%

  • RBGPF

    -13.5000

    69

    -19.57%

  • CMSD

    0.0950

    22.775

    +0.42%

  • VOD

    -0.0100

    14.71

    -0.07%

  • BP

    0.8600

    46.27

    +1.86%

  • RYCEF

    -0.6000

    15.3

    -3.92%

  • RELX

    -0.1400

    32.33

    -0.43%

  • CMSC

    -0.1000

    22.81

    -0.44%

Ketamine pill treats depression without psychedelic effects: study
Ketamine pill treats depression without psychedelic effects: study / Photo: © AFP/File

Ketamine pill treats depression without psychedelic effects: study

A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.

Text size:

First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".

However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.

In many countries, ketamine has been prescribed for depression for years.

US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".

The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.

Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.

There are also fears that medical use of the drug could slide into abuse.

The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.

"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.

"I don't think these tablets would appeal to people who are abusing ketamine."

- Electro-shock alternative -

The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.

More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.

Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.

Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.

Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.

"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.

This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.

But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".

- Fears of 'opioid style crisis' -

Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.

Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.

US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.

One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.

But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.

By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.

There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.

More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.

X.Silva--TFWP